Jenny Yeung

发表

Targeting acute myeloid cell surface using a recombinant antibody isolated from whole-cell biopanning of a phage display human scFv antibody library

K. Chester, M. Yamabhai, Thitima Sumphanapai, 2022, Medical Oncology.

E4BP4 expression is regulated by the t(17;19)‐associated oncoprotein E2A‐HLF in pro‐B cells

M. Hubank, H. Brady, Jenny Yeung, 2004, British journal of haematology.

Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells.

E. Halliwell, K. Chester, John Anderson, 2022, Cytotherapy.

Down syndrome acute lymphoblastic leukemia R 683 ) and multiple gene deletions in JAK 2 mutation ( JAK 2 Specific

K. Anderson, M. Greaves, L. Kearney, 2009 .

Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients' cells.

S. Bailey, M. Neat, H. Kempski, 2006, Haematologica.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

G. Lucchini, A. Hackshaw, P. Veys, 2019, Nature Medicine.

β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.

C. So, D. Bonnet, E. Griessinger, 2010, Cancer cell.

Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells.

Amanda J. Wilson, I. Huijbers, E. Taskesen, 2011, Cell stem cell.

A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats

K. Chester, S. Onuoha, B. Ma, 2020, Scientific Reports.

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

K. Anderson, M. Greaves, L. Kearney, 2009, Blood.

Specific JAK 2 mutation ( JAK 2 R 683 ) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

K. Anderson, M. Greaves, L. Kearney, 2009 .

Identification and characterization of hematopoietic stem and progenitor cell populations in mouse bone marrow by flow cytometry.

C. So, Jenny Yeung, 2009, Methods in molecular biology.

Antibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA

F. Lund-Johansen, P. Carter, T. Wurch, 2016, mAbs.

Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia.

C. So, J. Yeung, B. Zeisig, 2008, Cancer cell.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

G. Lucchini, A. Hackshaw, P. Veys, 2019, Nature Medicine.

Tyrosine kinase inhibitor insensitivity of non‐cycling CD34+ human acute myeloid leukaemia cells with FMS‐like tyrosine kinase 3 mutations

G. Morgan, M. Greaves, D. Gonzalez, 2011, British journal of haematology.

Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging

A. Plückthun, T. Meyer, K. Chester, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

G. Lucchini, A. Hackshaw, P. Veys, 2019, Blood.

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

M. Greaves, L. Kearney, S. Horsley, 2009, Blood.